Apellis Pharmaceuticals, Inc.
APLS
$18.20
$0.040.22%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 781.37M | 715.22M | 628.79M | 524.07M | 396.59M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 781.37M | 715.22M | 628.79M | 524.07M | 396.59M |
| Cost of Revenue | 445.29M | 417.28M | 396.98M | 399.97M | 412.90M |
| Gross Profit | 336.08M | 297.94M | 231.80M | 124.10M | -16.31M |
| SG&A Expenses | 501.05M | 521.27M | 544.94M | 528.23M | 500.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 946.35M | 938.55M | 941.92M | 928.20M | 913.71M |
| Operating Income | -164.98M | -223.33M | -313.13M | -404.13M | -517.12M |
| Income Before Tax | -196.72M | -247.80M | -330.95M | -415.25M | -526.50M |
| Income Tax Expenses | 1.16M | 2.30M | 1.94M | 2.02M | 2.13M |
| Earnings from Continuing Operations | -197.88 | -250.10 | -332.89 | -417.27 | -528.63 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -197.88M | -250.10M | -332.89M | -417.27M | -528.63M |
| EBIT | -164.98M | -223.33M | -313.13M | -404.13M | -517.12M |
| EBITDA | -163.18M | -221.51M | -311.30M | -402.32M | -515.34M |
| EPS Basic | -1.60 | -2.04 | -2.74 | -3.46 | -4.48 |
| Normalized Basic EPS | -0.98 | -1.25 | -1.69 | -2.15 | -2.79 |
| EPS Diluted | -1.60 | -2.04 | -2.74 | -3.46 | -4.48 |
| Normalized Diluted EPS | -0.98 | -1.25 | -1.69 | -2.15 | -2.79 |
| Average Basic Shares Outstanding | 495.62M | 492.33M | 488.39M | 483.80M | 474.71M |
| Average Diluted Shares Outstanding | 495.62M | 492.33M | 488.39M | 483.80M | 474.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |